Sulfated dietary fiber fucoidan protects gut microbiota from antibiotic collateral damage in preclinical models
Fucoidan reduced antibiotic-induced damage to gut microbiota in vitro, ex vivo, and in murine models, but no human data exist to support clinical application.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Growth of human gut microbial isolates under antibiotic pressure (in vitro) | D | ▲ Favorable | Broad-spectrum growth protection reported qualitatively; quantitative effect size and 95% CI not reported | 1 |
| Fecal community diversity ex vivo under antibiotic pressure | D | ▲ Favorable | Protective effect reported qualitatively; quantitative effect size and 95% CI not reported | 1 |
| Kanamycin-induced transcriptomic gene expression (in vitro) | D | ▲ Favorable | ~60% of kanamycin-induced genes counteracted by fucoidan; in the CI or effect size metric reported | 1 |
| Fucoidan-antibiotic physical binding (mass spectrometry, in vitro) | D | ▲ Favorable | Non-specific fucoidan-kanamycin binding detected; quantitative binding constants not reported | 1 |
| Gut microbiota recovery post-antibiotic treatment (in vivo, murine model) | D | ▲ Favorable | Facilitated recovery reported qualitatively in murine model; quantitative effect size and 95% CI not reported | 1 |
| Structural dependence of protective effect (molecular weight, sulfation, integrity) | D | ▲ Favorable | Loss of protection in desulfated, low-MW, and fragmented variants; comparative quantitative data not reported | 1 |
Context
Antibiotics disrupt commensal gut bacteria, promoting dysbiosis linked to metabolic, immunological, and neurological disease. Microbiota-protective strategies during antibiotic therapy remain understudied. Fucoidan, a sulfated marine polysaccharide, is a candidate due to its negative charge and capacity to interact with cationic molecules such as aminoglycosides.
What the study showed
Fucoidan protected human gut microbial isolates against multiple antibiotic classes in vitro and preserved fecal community diversity ex vivo. Transcriptomic analysis showed fucoidan counteracted approximately 60% of kanamycin-induced gene expression changes, suggesting functional antibiotic inhibition. Mass spectrometry indicated non-specific fucoidan-kanamycin binding in solution as the likely mechanism. In mice, fucoidan facilitated microbiota recovery post-antibiotic treatment. Absolute effect sizes, confidence intervals, and per-group sample sizes were not reported in the available text.
How it was done
Multimodal preclinical study: in vitro experiments with human gut microbial isolates, ex vivo fecal community experiments, transcriptomic analysis, mass spectrometry for fucoidan-antibiotic binding, and in vivo murine model experiments. Exact sample sizes, number of biological replicates, and in vivo experiment duration were not detailed in the provided text. No clinical (human) component was included.
Effect magnitude
Fucoidan counteracted ~60% of kanamycin-induced genes in transcriptomic analysis; quantitative effect sizes (SMD, RR, 95% CI) for microbial outcomes were not provided in the available summary.
Limitations
Complete absence of human data renders clinical applicability speculative. Murine microbiota differs substantially from human microbiota in composition and response. The non-specific fucoidan-antibiotic binding mechanism raises a critical concern: fucoidan may sequester the antibiotic and compromise therapeutic antimicrobial efficacy. No formal risk-of-bias tool (RoB 2, SYRCLE for animal studies) was mentioned. Sample sizes, randomization, and blinding in animal experiments were not reported in the available text.
In clinical practice
There is no basis for recommending fucoidan as a microbiota protector during antibiotic therapy. Clinicians should await randomized clinical trials in humans confirming efficacy and, critically, demonstrating that fucoidan does not impair therapeutic antimicrobial activity. The antibiotic sequestration concern is clinically relevant and unresolved.
What is still missing
Randomized clinical trials in humans are needed to evaluate efficacy and safety. It is a priority to determine whether fucoidan compromises antimicrobial efficacy in infection models and subsequently in humans.